BG107173A - 8 бета-хидрокарбил-заместени естратриени като селективно действащи естрогени - Google Patents
8 бета-хидрокарбил-заместени естратриени като селективно действащи естрогени Download PDFInfo
- Publication number
- BG107173A BG107173A BG107173A BG10717302A BG107173A BG 107173 A BG107173 A BG 107173A BG 107173 A BG107173 A BG 107173A BG 10717302 A BG10717302 A BG 10717302A BG 107173 A BG107173 A BG 107173A
- Authority
- BG
- Bulgaria
- Prior art keywords
- group
- hydrogen atom
- estra
- atom
- vinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10019167A DE10019167A1 (de) | 2000-04-12 | 2000-04-12 | Substituierte Estratriene als selektiv wirksame Estrogene |
| US20737000P | 2000-05-26 | 2000-05-26 | |
| PCT/EP2001/004290 WO2001077139A1 (de) | 2000-04-12 | 2001-04-12 | 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107173A true BG107173A (bg) | 2003-05-30 |
Family
ID=26005365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107173A BG107173A (bg) | 2000-04-12 | 2002-10-08 | 8 бета-хидрокарбил-заместени естратриени като селективно действащи естрогени |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7378404B2 (da) |
| EP (2) | EP1272504B1 (da) |
| JP (2) | JP3828423B2 (da) |
| CN (1) | CN100453549C (da) |
| AT (2) | ATE363487T1 (da) |
| AU (3) | AU5834101A (da) |
| BG (1) | BG107173A (da) |
| BR (1) | BR0109983A (da) |
| CA (1) | CA2406177C (da) |
| CZ (1) | CZ20023382A3 (da) |
| DE (1) | DE50112561D1 (da) |
| DK (2) | DK1272504T3 (da) |
| EA (1) | EA006299B1 (da) |
| EE (1) | EE200200589A (da) |
| ES (2) | ES2287127T3 (da) |
| HR (1) | HRP20020892B1 (da) |
| HU (1) | HUP0300335A2 (da) |
| IL (2) | IL152248A0 (da) |
| MX (1) | MXPA02010066A (da) |
| NO (2) | NO325337B1 (da) |
| NZ (1) | NZ543724A (da) |
| PL (1) | PL207488B1 (da) |
| PT (1) | PT1272504E (da) |
| SK (1) | SK14632002A3 (da) |
| WO (2) | WO2001077138A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0109983A (pt) * | 2000-04-12 | 2003-02-25 | Schering Ag | Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes |
| DE10027887A1 (de) | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| GB0020498D0 (en) | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
| DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
| DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
| DE60323938D1 (de) * | 2003-03-27 | 2008-11-20 | Pantarhei Bioscience Bv | Verwendung von Estrogenen zur Behandlung von Männerunfruchtbarkeit |
| DE10318896A1 (de) | 2003-04-22 | 2004-11-25 | Schering Ag | 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene |
| ES2307064T3 (es) * | 2003-11-26 | 2008-11-16 | Bayer Schering Pharma Aktiengesellschaft | Prevencion y tratamiento de enfermedades cardiacas hipertensivas por los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol. |
| US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
| DE102005057225A1 (de) * | 2005-11-29 | 2007-05-31 | Bayer Schering Pharma Ag | Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DE102005057224A1 (de) * | 2005-11-29 | 2007-05-31 | Bayer Schering Pharma Ag | Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| EP2014672A1 (en) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | 8-beta-substituted estratrienes as selectively active estrogens |
| NZ586666A (en) * | 2008-02-13 | 2012-04-27 | Bayer Schering Pharma Ag | Estradiol-containing drug delivery system |
| EA018330B1 (ru) * | 2008-02-13 | 2013-07-30 | Байер Интеллекчуал Проперти Гмбх | Система доставки лекарственного средства со стабилизирующим эффектом |
| EP2143432A1 (en) | 2008-07-11 | 2010-01-13 | Bayer Schering Pharma AG | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer |
| WO2010057594A1 (en) * | 2008-11-21 | 2010-05-27 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2743E (fr) * | 1902-01-11 | 1904-12-15 | Adolphe Ernest Pointe | Panification augmentant le rendement et la digestibilité |
| JPS454059Y1 (da) * | 1967-11-04 | 1970-02-25 | ||
| JPS454060Y1 (da) * | 1967-12-11 | 1970-02-25 | ||
| US3501530A (en) * | 1968-02-27 | 1970-03-17 | American Cyanamid Co | Substituted naphthalenones,naphthalenediones and d-homo - beta - nor estra-1,3,5(10),9(11)-tetraenes |
| US3681407A (en) * | 1969-06-18 | 1972-08-01 | American Cyanamid Co | 3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof |
| US3806546A (en) * | 1969-06-18 | 1974-04-23 | American Cyanamid Co | Steroid-like compounds and method of synthesis |
| US3709878A (en) * | 1970-07-20 | 1973-01-09 | Sandoz Ag | 8 alpha-methyl-substituted-steroids |
| US3736345A (en) * | 1971-05-18 | 1973-05-29 | American Cyanamid Co | Steroid-like compounds and method of synthesis |
| US4961931A (en) | 1982-07-29 | 1990-10-09 | Alza Corporation | Method for the management of hyperplasia |
| DE4018828C2 (de) * | 1989-06-08 | 1999-05-12 | Schering Ag | Verfahren zur Herstellung C7-alpha-substituierter 8alpha- und 8ß-Estra-1,3,5(10)-triene und C8-alpha-substituierter Estra-1,3,5(10)-triene sowie neue Zwischenprodukte für dieses Verfahren |
| WO1997041145A1 (en) * | 1996-05-01 | 1997-11-06 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
| DE69902684T2 (de) * | 1998-11-20 | 2003-04-24 | Akzo Nobel N.V., Arnheim/Arnhem | Estrogenische estra-1,3,5(10)-trien verbindungen mit verschiedenen wirkungen auf estrogenrezeptor alpha und beta mit einer unverzweigten kohlenwasserstoffkette von 5-9 kohlenstoffatomen in position 11 |
| DE10019167A1 (de) * | 2000-04-12 | 2001-10-18 | Schering Ag | Substituierte Estratriene als selektiv wirksame Estrogene |
| BR0109983A (pt) * | 2000-04-12 | 2003-02-25 | Schering Ag | Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes |
| DE10318896A1 (de) * | 2003-04-22 | 2004-11-25 | Schering Ag | 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene |
-
2001
- 2001-04-12 BR BR0109983-3A patent/BR0109983A/pt not_active IP Right Cessation
- 2001-04-12 AT AT01931609T patent/ATE363487T1/de active
- 2001-04-12 US US10/257,288 patent/US7378404B2/en not_active Expired - Fee Related
- 2001-04-12 DE DE50112561T patent/DE50112561D1/de not_active Expired - Lifetime
- 2001-04-12 CA CA2406177A patent/CA2406177C/en not_active Expired - Fee Related
- 2001-04-12 AU AU5834101A patent/AU5834101A/xx active Pending
- 2001-04-12 HR HR20020892A patent/HRP20020892B1/xx not_active IP Right Cessation
- 2001-04-12 US US10/257,287 patent/US20040029847A1/en not_active Abandoned
- 2001-04-12 WO PCT/EP2001/004289 patent/WO2001077138A1/de not_active Ceased
- 2001-04-12 JP JP2001575608A patent/JP3828423B2/ja not_active Expired - Lifetime
- 2001-04-12 CZ CZ20023382A patent/CZ20023382A3/cs unknown
- 2001-04-12 NZ NZ543724A patent/NZ543724A/en unknown
- 2001-04-12 CN CNB018107745A patent/CN100453549C/zh not_active Expired - Fee Related
- 2001-04-12 HU HU0300335A patent/HUP0300335A2/hu unknown
- 2001-04-12 AU AU2001258341A patent/AU2001258341B2/en not_active Ceased
- 2001-04-12 DK DK01931609T patent/DK1272504T3/da active
- 2001-04-12 PT PT01931609T patent/PT1272504E/pt unknown
- 2001-04-12 WO PCT/EP2001/004290 patent/WO2001077139A1/de not_active Ceased
- 2001-04-12 MX MXPA02010066A patent/MXPA02010066A/es active IP Right Grant
- 2001-04-12 SK SK1463-2002A patent/SK14632002A3/sk unknown
- 2001-04-12 IL IL15224801A patent/IL152248A0/xx active IP Right Grant
- 2001-04-12 EP EP01931609A patent/EP1272504B1/de not_active Expired - Lifetime
- 2001-04-12 PL PL358667A patent/PL207488B1/pl not_active IP Right Cessation
- 2001-04-12 EP EP01940331A patent/EP1272505B1/de not_active Expired - Lifetime
- 2001-04-12 AT AT01940331T patent/ATE302790T1/de not_active IP Right Cessation
- 2001-04-12 EE EEP200200589A patent/EE200200589A/xx unknown
- 2001-04-12 AU AU2001273945A patent/AU2001273945A1/en not_active Abandoned
- 2001-04-12 ES ES01931609T patent/ES2287127T3/es not_active Expired - Lifetime
- 2001-04-12 EA EA200201052A patent/EA006299B1/ru not_active IP Right Cessation
- 2001-04-12 ES ES01940331T patent/ES2245694T3/es not_active Expired - Lifetime
- 2001-04-12 DK DK01940331T patent/DK1272505T3/da active
-
2002
- 2002-10-08 BG BG107173A patent/BG107173A/bg unknown
- 2002-10-10 IL IL152248A patent/IL152248A/en not_active IP Right Cessation
- 2002-10-11 NO NO20024908A patent/NO325337B1/no unknown
- 2002-10-11 NO NO20024907A patent/NO20024907L/no not_active Application Discontinuation
-
2008
- 2008-03-11 US US12/045,979 patent/US20080182829A1/en not_active Abandoned
- 2008-06-25 JP JP2008166585A patent/JP2008280355A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG107173A (bg) | 8 бета-хидрокарбил-заместени естратриени като селективно действащи естрогени | |
| EP1169336B1 (en) | Ent-steroids as selectively active estrogens | |
| US6958327B1 (en) | 18 Norsteroids as selectively active estrogens | |
| US7414043B2 (en) | 9-α-substituted estratrienes as selectively active estrogens | |
| CA2359660A1 (en) | 16-hydroxyestratrienes as selective estrogens | |
| CA2486495C (en) | 9-alpha-substituted estratrienes as selectively active estrogens | |
| JP2003513102A (ja) | 選択的な作用を有するエストロゲンとしての18−ノル−ステロイド | |
| KR100825534B1 (ko) | 선택적 에스트로겐으로 유용한 8베타-히드로카르빌 치환된에스트라트리엔 | |
| US20060270845A1 (en) | 16-Hydroxyestratrienes as selectively active estrogens | |
| AU2008274198A1 (en) | 8-beta-substituted estratrienes as selectively active estrogens | |
| US20050282791A1 (en) | 18-nor steroids as selectively active estrogens | |
| AU2004201405A1 (en) | Ent-Steroids as selectively active estrogens | |
| NZ536882A (en) | 9-Alpha-substituted estratrienes as selectively active estrogens | |
| HK1057219B (en) | 8.beta-.hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene |